Accordingly, we focused on the relationship between breast cancer arising from BRCA1 loss and increased tumor mutational burden, with the aim of assessing its potential as a predictive indicator for improved outcomes with immune checkpoint inhibitor (ICI) therapy. This evidence concerns the gene BRCA1 and breast carcinoma.